Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.
5-HT2A receptor
LSD
new psychoactive substances
psychedelics
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
21
04
2022
received:
22
03
2022
accepted:
05
05
2022
pubmed:
8
5
2022
medline:
9
8
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Lysergic acid diethylamide (LSD) is known to induce powerful psychoactive effects in humans, which cemented its status as an important tool for clinical research. A range of analogues and derivatives has been investigated over the years, including those classified as new psychoactive substances. This study presents the characterization of the novel lysergamide N,N-diethyl-1-propanoyl-6-(prop-2-en-1-yl)-9,10-didehydroergoline-8β-carboxamide (1P-AL-LAD) using various mass spectrometric, gas- and liquid chromatographic and spectroscopic methods. In vitro metabolism studies using pooled human liver microsomes (pHLM) confirmed that 1P-AL-LAD converted to AL-LAD as the most abundant metabolite consistent with the hypothesis that 1P-AL-LAD may act as a prodrug. Fourteen metabolites were detected in total; metabolic reactions included hydroxylation of the core lysergamide ring structure or the N
Identifiants
pubmed: 35524430
doi: 10.1002/dta.3281
pmc: PMC9546273
doi:
Substances chimiques
Hallucinogens
0
Prodrugs
0
lysergamide
073830XH10
Lysergic Acid Diethylamide
8NA5SWF92O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1503-1518Subventions
Organisme : Internal Security Fund of the European Union
ID : IZ25-5793-2019-33
Organisme : NIDA NIH HHS
ID : R01 DA041336
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA041336
Pays : United States
Informations de copyright
© 2022 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
J Med Chem. 1985 Sep;28(9):1252-5
pubmed: 4032428
Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
J Pharm Biomed Anal. 2019 Sep 10;174:270-276
pubmed: 31181490
Anal Bioanal Chem. 2019 Jul;411(19):4751-4763
pubmed: 30617391
Drug Metab Rev. 2019 Aug;51(3):378-387
pubmed: 31266388
Pharmacopsychiatry. 2021 Jul;54(4):176-190
pubmed: 33472250
Neuron. 2007 Feb 1;53(3):439-52
pubmed: 17270739
Eur J Pharmacol. 1977 Oct 15;45(4):341-8
pubmed: 923645
Pharmacopsychiatry. 2021 Jul;54(4):151-166
pubmed: 33285579
Neuropharmacology. 2020 May 1;167:107933
pubmed: 31917152
Yakugaku Zasshi. 1976 May;96(5):673-8
pubmed: 987200
Curr Top Behav Neurosci. 2018;36:159-199
pubmed: 28224459
Behav Brain Res. 2015 Jan 15;277:99-120
pubmed: 25036425
Drug Test Anal. 2019 Aug;11(8):1122-1133
pubmed: 31083768
Drug Test Anal. 2020 Jun;12(6):812-826
pubmed: 32180350
NIDA Res Monogr. 1994;146:52-73
pubmed: 8742794
Sci Rep. 2020 May 20;10(1):8344
pubmed: 32433580
Drug Alcohol Depend. 2020 Jul 1;212:108071
pubmed: 32450479
Drug Test Anal. 2016 Sep;8(9):891-902
pubmed: 26456305
Curr Top Behav Neurosci. 2022;56:23-34
pubmed: 35091980
Pharmacopsychiatry. 2022 May;55(3):121-138
pubmed: 35079988
Neuropharmacology. 2020 Aug 1;172:107856
pubmed: 31756337
Curr Top Behav Neurosci. 2018;36:221-256
pubmed: 28025814
Mol Pharmacol. 1994 Feb;45(2):277-86
pubmed: 8114677
Psychopharmacology (Berl). 1995 Apr;118(4):401-9
pubmed: 7568626
Int Rev Psychiatry. 2018 Aug;30(4):291-316
pubmed: 30422079
Arch Int Pharmacodyn Ther. 1977 Aug;228(2):314-21
pubmed: 303504
Psychopharmacology (Berl). 2013 Jun;227(4):727-39
pubmed: 23407781
Yakugaku Zasshi. 2020;140(5):739-750
pubmed: 32378678
Drug Test Anal. 2020 Aug;12(8):1144-1153
pubmed: 32415750
Drug Test Anal. 2017 Jan;9(1):38-50
pubmed: 27265891
Drug Test Anal. 2022 Aug;14(8):1503-1518
pubmed: 35524430
Nat Rev Neurosci. 2020 Nov;21(11):611-624
pubmed: 32929261
Pharmacopsychiatry. 1998 Jul;31 Suppl 2:80-4
pubmed: 9754838
Drug Test Anal. 2017 Oct;9(10):1641-1649
pubmed: 28342178
Drug Test Anal. 2022 Apr;14(4):733-740
pubmed: 34837347
Curr Top Behav Neurosci. 2018;36:1-43
pubmed: 28401524